Login / Signup

Use of dupilumab in a patient with atopic dermatitis, severe asthma, and HIV infection.

Petra BrodskaPetr PanznerDalibor SedlacekMilan TerlPetra Cetkovska
Published in: Dermatologic therapy (2020)
Dupilumab is a monoclonal antibody against interleukin 4 (IL-4) receptor α that blocks signaling from IL-4 and IL-13, essential mediators of T helper 2 (Th2) pathway. To date, all clinical trials investigating the use of dupilumab excluded patients with human immunodeficiency virus. Herein, we describe the safe and successful use of dupilumab in a patient with atopic dermatitis, severe therapy resistant asthma, and HIV infection.
Keyphrases